Clinical Trials Browser

INDUSTRY × Urinary Bladder Diseases × Nivolumab × Clear all

NCT04200963 2024-03-15

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Phase 1 Completed

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms